Skip to main content
SpringerLink
Log in

Peripheral Arterial Disease

  • Chapter
Geriatric Medicine

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc. 1985;33:13–18.

    PubMed  CAS  Google Scholar 

  2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley diabetes study. Circulation. 1995;91:1472–1479.

    PubMed  CAS  Google Scholar 

  3. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386.

    Article  PubMed  CAS  Google Scholar 

  4. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA. 1993;270:465–469.

    Article  PubMed  CAS  Google Scholar 

  5. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc. 1997;45:1472–1478.

    PubMed  CAS  Google Scholar 

  6. Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J. 1996;313:1440–1444.

    CAS  Google Scholar 

  7. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25:1172–1181.

    PubMed  CAS  Google Scholar 

  8. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol. 1994;23:1091–1095.

    Article  PubMed  CAS  Google Scholar 

  9. Vogt MT, Cauley JA, Kuller LH, Hulley SB. Prevalence and correlates of lower extremity arterial disease in elderly women. Am J Epidemiol. 1993;137:559–568.

    PubMed  CAS  Google Scholar 

  10. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes. 1980;29:882–888.

    PubMed  CAS  Google Scholar 

  11. Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96:44–49.

    PubMed  CAS  Google Scholar 

  12. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982; 69(suppl):S24–S26.

    PubMed  Google Scholar 

  13. Stewart CP. The influence of smoking on the level of lower limb amputation. Prosthet Orthot Int. 1987;11:113–116.

    PubMed  CAS  Google Scholar 

  14. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180–1188.

    PubMed  CAS  Google Scholar 

  15. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133–138.

    PubMed  CAS  Google Scholar 

  16. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050.

    Article  PubMed  CAS  Google Scholar 

  17. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338–342.

    PubMed  CAS  Google Scholar 

  18. Donaldson MC, Weinberg DS, Belkin M, Whittemore AD, Mannick JA. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. J Vasc Surg. 1990; 11:825–831.

    Article  PubMed  CAS  Google Scholar 

  19. Catalano M, Russo U, Libretti A. Plasma beta-thromboglobulin levels and claudication degrees in patients with peripheral vascular disease. Angiology. 1986;37:339–342.

    PubMed  CAS  Google Scholar 

  20. England JD, Regensteiner JG, Ringel SP, Carry MR, Hiatt WR. Muscle denervation in peripheral arterial disease. Neurology. 1992;42:994–999.

    PubMed  CAS  Google Scholar 

  21. Regensteiner JG, Wolfel EE, Brass EP, et al. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation. 1993;87:413–421.

    PubMed  CAS  Google Scholar 

  22. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol. 1992;73:346–353.

    PubMed  CAS  Google Scholar 

  23. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation. 1999;99:807–812.

    PubMed  CAS  Google Scholar 

  24. Brass EP, Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease. Vasc Med. 2000;5:55–59.

    Article  PubMed  CAS  Google Scholar 

  25. Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am J Physiol. 2001;280:H603–H609.

    CAS  Google Scholar 

  26. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol. 1999;87:809–816.

    PubMed  CAS  Google Scholar 

  27. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–1324.

    Article  PubMed  CAS  Google Scholar 

  28. Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969;207:1869–1874.

    Article  PubMed  CAS  Google Scholar 

  29. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation. 1995;92:614–621.

    PubMed  CAS  Google Scholar 

  30. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104–115.

    PubMed  CAS  Google Scholar 

  31. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand. 1987;221:253–260.

    Article  PubMed  CAS  Google Scholar 

  32. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691.

    Article  PubMed  CAS  Google Scholar 

  33. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–1798.

    Article  PubMed  CAS  Google Scholar 

  34. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894–903.

    Google Scholar 

  35. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853.

    Google Scholar 

  36. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652.

    Article  PubMed  CAS  Google Scholar 

  37. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303.

    Google Scholar 

  38. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284:1263–1270.

    Article  PubMed  CAS  Google Scholar 

  39. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 1999.

    Google Scholar 

  40. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;329:3015–3023.

    Google Scholar 

  41. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA. 1999;282: 2051–2057.

    Article  PubMed  CAS  Google Scholar 

  42. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–2446.

    Google Scholar 

  43. Hiatt WR, Stoll S, Nies AS. Effect of β-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation. 1985;72:1226–1231.

    PubMed  CAS  Google Scholar 

  44. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151:1769–1776.

    Article  PubMed  CAS  Google Scholar 

  45. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999;341:1789–1794.

    Article  PubMed  CAS  Google Scholar 

  46. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153.

    Article  Google Scholar 

  47. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340: 1449–1454.

    Article  PubMed  CAS  Google Scholar 

  48. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199–208.

    Article  Google Scholar 

  49. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613.

    Article  PubMed  CAS  Google Scholar 

  50. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J. 1988;296:320–331.

    Article  Google Scholar 

  51. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106.

    Google Scholar 

  52. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J. 1994;308:159–168.

    Google Scholar 

  53. Bokissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemostasis. 1996;62:681–685.

    Google Scholar 

  54. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology. 1988;39:802–811.

    PubMed  CAS  Google Scholar 

  55. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339.

    Article  Google Scholar 

  56. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A metaanalysis. JAMA. 1995;274:975–980.

    Article  PubMed  CAS  Google Scholar 

  57. Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979;300:713–717.

    Article  PubMed  CAS  Google Scholar 

  58. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982; 104:66–72.

    Article  PubMed  CAS  Google Scholar 

  59. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–530.

    Article  PubMed  CAS  Google Scholar 

  60. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337–345.

    Article  PubMed  CAS  Google Scholar 

  61. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 1999;96:261–268.

    Article  PubMed  CAS  Google Scholar 

  62. Igawa T, Tani T, Chijiwa J, et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990;57:617–623.

    Article  PubMed  CAS  Google Scholar 

  63. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21–26.

    PubMed  CAS  Google Scholar 

  64. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159: 2041–2050.

    Article  PubMed  CAS  Google Scholar 

  65. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267–274.

    Article  PubMed  CAS  Google Scholar 

  66. Dawson DL, Cutler BS, Meissner MH, Strandness DEJ. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678–686.

    PubMed  CAS  Google Scholar 

  67. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-l-carnitine in intermittent claudication: doubleblind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol. 1995;26:1411–1416.

    Article  PubMed  CAS  Google Scholar 

  68. Brevetti G, Diehm C, Lambett D. European multicenter study on propionyl-l-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618–1624.

    Article  PubMed  CAS  Google Scholar 

  69. Brevetti G, Perna S, Sabba C, et al. Effect of propionyl-l-carnitine on quality of life in intermittent claudication. Am J Cardiol. 1997;79:777–780.

    Article  PubMed  CAS  Google Scholar 

  70. Lievre M, Morand S, Besse B, et al. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Circulation. 2000;102:426–431.

    PubMed  CAS  Google Scholar 

  71. Mannarino E, Pasqualini L, Innocente S, et al. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? Angiology. 1991;42:513–521.

    PubMed  CAS  Google Scholar 

  72. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation. 1994;90:818–822.

    PubMed  CAS  Google Scholar 

  73. Dormandy JA, Murray GD. The fate of the claudicant: a prospective study of 1969 claudicants. Eur J Vasc Surg. 1991;5:131–133.

    Article  PubMed  CAS  Google Scholar 

  74. O’Riordain DS, O’Donnell JA. Realistic expectations for the patient with intermittent claudication. Br J Surg. 1991; 78:861–863.

    PubMed  CAS  Google Scholar 

  75. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis. J Vasc Surg. 1989;9:1–8.

    Article  PubMed  CAS  Google Scholar 

  76. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. J Vasc Surg. 2000;31:S1–S296.

    Article  PubMed  CAS  Google Scholar 

  77. Poulias GE, Doundoulakis N, Prombonas E, et al. Aortofemoral bypass and determinants of early success and late favourable outcome. Experience with 1000 consecutive cases. J Cardiovasc Surg. 1992;33:664–678.

    CAS  Google Scholar 

  78. Lorentzen JE, Nielsen OM, Arendrup H, et al. Vascular graft infection: an analysis of sixty-two graft infections in 2411 consecutively implanted synthetic vascular grafts. Surgery. 1985;98:81–86.

    PubMed  CAS  Google Scholar 

  79. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluorethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986; 3:104–114.

    Article  PubMed  CAS  Google Scholar 

  80. Dalman RL, Taylor LM. Basic data related to infrainguinal revascularization procedures. Ann Vasc Surg. 1990;4:309–312.

    Article  PubMed  CAS  Google Scholar 

  81. Samson RH, Veith FJ, Janko GS, Gupta SK, Scher LA. A modified classification and approach to the management of infections involving peripheral arterial prosthetic grafts. J Vasc Surg. 1988;8:147–153.

    Article  PubMed  CAS  Google Scholar 

  82. Nehler MR, Moneta GL, Edwards JM, et al. Surgery for chronic lower extremity ischemia in patients eighty or more years of age: operative results and assessment of postoperative independence. J Vasc Surg. 1993;18:618–626.

    Article  PubMed  CAS  Google Scholar 

  83. Nehler MR, Moneta GL, Yeager RA, et al. Surgical treatment of threatened reversed infrainguinal vein grafts. J Vasc Surg. 1994;20:558–565.

    PubMed  CAS  Google Scholar 

  84. Nicoloff AD, Taylor LMJ, McLafferty RB, Moneta GL, Porter JM. Patient recovery after infrainguinal bypass grafting for limb salvage. J Vasc Surg. 1998;27:256–263.

    Article  PubMed  CAS  Google Scholar 

  85. Yamanaka M, Kwong PK. The side-to-side flap technique in below-the-knee amputation with long stump. Clin Orthop. 1985;201:75–79.

    PubMed  Google Scholar 

  86. Robinson KP. Long posterior flap amputation in geriatric patients with ischaemic disease. Ann R Coll Surg Engl. 1976;58:440–451.

    PubMed  CAS  Google Scholar 

  87. Silverman DG, Roberts A, Reilly CA, et al. Fluorometric quantification of low-dose fluorescein delivery to predict amputation site healing. Surgery. 1987;101:335–341.

    PubMed  CAS  Google Scholar 

  88. Tripses D, Pollak EW. Risk factors in healing of below-knee amputation. Appraisal of 64 amputations in patients with vascular disease. Am J Surg. 1981;141:718–720.

    Article  PubMed  CAS  Google Scholar 

  89. Kihn RB, Warren R, Beebe GW. The “geriatric” amputee. Ann Surg. 1972;176:305–314.

    PubMed  CAS  Google Scholar 

  90. Rigdon EE, Monajjem N, Rhodes RS. Criteria for selective utilization of the intensive care unit following carotid endarterectomy. Ann Vasc Surg. 1997;11:20–27.

    Article  PubMed  CAS  Google Scholar 

  91. Gregg RO. Bypass or amputation? Concomitant review of bypass arterial grafting and major amputations. Am J Surg. 1985;149:397–402.

    PubMed  CAS  Google Scholar 

  92. Cameron HC. Amputations in the diabetic: outcome and survival. Lancet. 1964;ii:605–607.

    Article  Google Scholar 

  93. Rush DS, Huston CC, Bivins BA, Hyde GL. Operative and late mortality rates of above-knee and below-knee amputations. Am Surg. 1981;47:36–39.

    PubMed  CAS  Google Scholar 

  94. Whitehouse FW, Jurgensen C, Block MA. The later life of the diabetic amputee: another look at the fate of the second leg. Diabetes. 1968;17:520–521.

    PubMed  CAS  Google Scholar 

  95. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;12:209–215.

    Article  PubMed  CAS  Google Scholar 

  96. Orchard TJ, Strandness DE, Cavanagh PR, et al. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop. Circulation. 1993;88:819–828.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. William R. Hiatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark R. Nehler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Hiatt, W.R., Nehler, M.R. (2003). Peripheral Arterial Disease. In: Geriatric Medicine. Springer, New York, NY. https://doi.org/10.1007/0-387-22621-4_42

Download citation

  • DOI: https://doi.org/10.1007/0-387-22621-4_42

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95514-8

  • Online ISBN: 978-0-387-22621-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation